EQ

Healthcare Biotechnology

Equillium, Inc.

$1.44

-0.08 -5.26% today Live

Price History

Not enough data

Price chart data
Date	Price
Oct 6, 2026, live at 2:21 PM ET	1.44

Key Stats

Market Cap

91.31M

Avg Volume

625,704

EPS

-$0.14

52W High

$3.54

52W Low

$0.76

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-6.15

P/B Ratio

1.63

EV/EBITDA

-1.84

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(59.0%)

Return on Assets

(34.0%)

Liquidity & Leverage

Current Ratio

23.40

Quick Ratio

23.07

Debt / Equity

0.01

Total Cash

57.16M

Total Debt

584,000

About

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.